Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Jump-Start Your Search For Promising Trade Ideas With Barchart Premier’s "Top Stock Pick". FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or
Boston Scientific Corp (BSX)
Boston Scientific Corp (BSX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Profile for [[ item.sessionDateDisplayLong ]]

Company Info

Boston Scientific Corp 300 BOSTON SCIENTIFIC WAY MARLBOROUGH MA 01752 USA

www.bostonscientific.com P: 508-683-4000 F: 508-650-8923

Description:

Boston Scientific Corporation manufactures medical devices and products used in various interventional medical specialties worldwide. The company has adopted the organic as well as inorganic routes for success. Boston Scientific currently has 3 global reportable segments - Cardiovascular, Rhythm and Neuro and MedSurg. While Cardiovascular includes Interventional Cardiology and Peripheral Interventions, Rhythm and Neuro comprises Cardiac Rhythm Management, Electrophysiology and Neuromodulation. The MedSurg group comprises 2 sub segments, viz. Endoscopy, Urology and Pelvic Health. Boston Scientific markets a broad portfolio of internally-developed and self-manufactured drug eluting stents including the Promus PREMIER, Promus Element and Promus Element Plus everolimus-eluting stents. Within the CRM segment, the company deals with implantable devices that monitor the heart and deliver electricity to treat cardiac abnormalities.

Key Statistics

Overview:

Market Capitalization, $K 80,310,368
Enterprise Value, $K 88,317,368
Shares Outstanding, K 1,464,983
Annual Sales, $ 12,682 M
Annual Net Income, $ 698,000 K
Last Quarter Sales, $ 3,527 M
Last Quarter Net Income, $ 504,000 K
EBIT, $ 2,978 M
EBITDA, $ 4,246 M
60-Month Beta 0.78
% of Insider Shareholders 0.71%
% of Institutional Shareholders 89.11%
Float, K 1,454,582
% Float 99.29%
Short Volume Ratio 0.48

Growth:

1-Year Return 20.60%
3-Year Return 63.78%
5-Year Return 53.72%
5-Year Revenue Growth 40.16%
5-Year Earnings Growth 35.71%
5-Year Dividend Growth 0.00%

Per-Share Information:

Most Recent Earnings 0.50 on 10/26/23
Next Earnings Date N/A
Earnings Per Share ttm 1.95
EPS Growth vs. Prev Qtr -5.66%
EPS Growth vs. Prev Year 16.28%
Annual Dividend Yield 0.00%
Dividend Payout Ratio 0.00%
Most Recent Split 2-1 on 11/06/03

BSX Ratios

Ratio
Price/Earnings ttm 28.14
Price/Earnings forward 27.28
Price/Earnings to Growth 2.18
Return-on-Equity % 15.46%
Return-on-Assets % 8.52%
Profit Margin % 5.50%
Net Margin % 7.57
Debt/Equity 0.47
Price/Sales 6.34
Price/Cash Flow 21.05
Price/Book 4.19
Book Value/Share 13.06
Interest Coverage 3.43
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar